Although it is well recognized that haematopoietic stem cells (HSCs) develop from a specialized population of endothelial cells known as haemogenic endothelium, the regulatory pathways that control this transition are not well defined. Here we identify Sox17 as a key regulator of haemogenic endothelial development. Analysis of Sox17 -GFP reporter mice revealed that Sox17 is expressed in haemogenic endothelium and emerging HSCs and that it is required for HSC development. Using the mouse embryonic stem cell differentiation model, we show that Sox17 is also expressed in haemogenic endothelium generated in vitro and that it plays a pivotal role in the development and/or expansion of haemogenic endothelium through the Notch signalling pathway. Taken together, these findings position Sox17 as a key regulator of haemogenic endothelial and haematopoietic development.
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Although it is well recognized that haematopoietic stem cells (HSCs) develop from a specialized population of endothelial cells known as haemogenic endothelium, the regulatory pathways that control this transition are not well defined. Here we identify Sox17 as a key regulator of haemogenic endothelial development. Analysis of Sox17 -GFP reporter mice revealed that Sox17 is expressed in haemogenic endothelium and emerging HSCs and that it is required for HSC development. Using the mouse embryonic stem cell differentiation model, we show that Sox17 is also expressed in haemogenic endothelium generated in vitro and that it plays a pivotal role in the development and/or expansion of haemogenic endothelium through the Notch signalling pathway. Taken together, these findings position Sox17 as a key regulator of haemogenic endothelial and haematopoietic development.
The embryonic haematopoietic system consists of two distinct programs that differ in their potential and temporal patterns of development. Primitive haematopoiesis emerges in the yolk sac and exhibits restricted potential, generating primitive erythroblasts, macrophages, megakaryocytes but no lymphoid lineage cells or HSCs (refs 1,2) . HSCs are generated during definitive haematopoiesis derived from haemogenic endothelium that is specified at different sites, the best characterized being the region comprising the developing aorta, gonads and mesonephros [3] [4] [5] (AGM). Histological analyses and imaging studies have shown that the haematopoietic cells bud from the haemogenic endothelium through a process known as the endothelial to haematopoietic transition (EHT) and subsequently form distinct clusters within the lumen of the aorta [6] [7] [8] . Numerous studies have identified key regulators of this process including HoxA3 that plays a role in the development of haemogenic endothelium and Notch1 and Runx1 that function during the EHT (refs 9-11). The SoxF family of transcription factors, Sox7, Sox17 and Sox18, have also been shown to play a role in embryonic haematopoiesis [12] [13] [14] . Sox17 is of particular interest in this context as it is expressed in the arterial vasculature 15, 16 , and required for the generation and maintenance of HSCs in the mouse fetal liver 17 , and its expression marks progenitors that contribute to haemogenic endothelial and adult definitive haematopoiesis 18 . We previously reported that expression of Sox17 together with Flk-1 identifies a definitive haematopoietic progenitor in mouse embryonic stem cell (mESC) differentiation cultures and distinguishes it from an earlier developing Flk-1 + Sox17 − population that represents the primitive haematopoietic program 19 . To further characterize this Sox17
+ population with respect to haemogenic endothelium, we used a reporter mESC line carrying a targeted Sox17 -mCherry fusion complementary DNA (Sox17-mC; ref. 20) to track its development. When differentiated in defined culture conditions (Fig. 1a) the Sox17-mC mESC line generates a Flk-1 + Sox17-mC − population within 3.0 to 3.25 days (D) of culture (Fig. 1b) . Although these early progenitors do not express Sox17 as they emerge, they do give rise to Sox17
+ cells that co-express the endothelial markers Flk-1, VE-cadherin (VEC) and CD31 following a further 24 h of culture ( Supplementary Fig. S1a ). Whether this Sox17
+ population represents the developing primitive erythroid lineage, definitive haematopoietic progenitors contaminating the D3.25 Flk-1 + population 19 or emerging endothelial progenitors remains to be determined.
To examine the role of Sox17 in the generation of the definitive haematopoietic program, D3.25 embryoid bodies were dissociated and reaggregated for two days (D5.25) to induce a second population of Flk-1 + cells that does express Sox17-mC. Fluorescence-activated cell sorting (FACS) analysis revealed that the D5.25 Sox17-mC + cells also expressed VEC, CD31 and AA4.1 (CD93). Most D5.25 Sox17-mC + cells did not express CD41 nor CXCR4 and none expressed Sca-1 (Ly6a; Fig. 1b ). Real-time PCR with reverse transcription (qRT-PCR) analysis confirmed Sox17 expression at D5.25 of differentiation ( Supplementary Fig. S1b ).
To determine whether the Flk-1 + Sox17-mC + cells exhibit haemogenic endothelial potential the F + S + , F + S − and F − S − populations were isolated from D5.25 embryoid bodies ( Fig. 1c and Supplementary Fig. S1b ) and plated as a monolayer with cytokines (d) Haematopoietic progenitor potential of D5.25 sorted fractions depicted in c cultured for 4 days. D9 aggregates were dissociated and the cells plated in methylcellulose cultures that were scored for definitive erythroid (D-Ery), macrophage and monocyte (Mac) or granulocyte, erythrocyte, macrophage and megakaryocyte (Mixed) colonies after 8 days in culture. Bars represent standard deviation of the mean of 3 independent experiments; * * * P = 0.003. (e) T-lymphoid potential of the D5.25 sorted fractions cultured for 4 days. D9 aggregates were dissociated and the cells plated on irradiated OP9-DL1 stromal cells in limiting dilution for 21 days. Positive wells were those that contained more than 500 cells of which more than 5% expressed the T-cell signature CD45 + TCRβ + CD4 + /CD8 + . Bars represent standard deviation of the mean of 3 independent experiments; * * * P = 0.0001.
L E T T E R S
known to promote the growth of endothelial cells. Molecular analyses showed that F + S + cells expressed the highest levels of Sox17, verifying the fidelity of the mCherry reporter ( Supplementary Fig. S1b ). Following two days of culture a significant proportion of the population derived from the F + S + fraction downregulated expression of both VEC and Sox17-mC and upregulated the expression of CD45, suggesting that these cells initiated the EHT (Fig. 1c) . The F + S − fraction gave rise to a population with a similar profile, including cells that co-express VEC and Sox17-mC, suggesting that the F + S − fraction contains progenitors of the F + S + population. The F − S − fraction showed little capacity to generate haemogenic endothelium.
To promote haematopoietic development, the monolayers were dissociated and cultured as aggregates in haematopoietic cytokines for two days (Fig. 1a) . During this time, the F + S + and F + S − -derived cells downregulated Sox17-mC expression and generated CD45
+ VEC − cells. The F − S − fraction did not give rise to any CD45 + cells, indicating that haematopoietic potential was restricted to populations that expressed or acquired expression of F + Sox17-mC (Fig. 1c) . The population derived from the F + S + fraction contained the highest frequency of myeloid and multipotent progenitors and was the only one that generated T cells (Fig. 1d,e) . qRT-PCR analyses revealed that cells generated from the F + S + and F + S − fractions also expressed the highest levels of Aml1c (Supplementary Fig. S1c ). Taken together, these findings demonstrate that Sox17 expression marks the emergence of haemogenic endothelium in mESC differentiation cultures.
To investigate the role of Sox17 in the generation of definitive haematopoiesis in vivo, we analysed the AGM region of embryonic day (E)11.5 Sox17 GFP/+ embryos 17 for expression of Sox17-GFP. As shown in Fig. 2a , a distinct Sox17-GFP + population was detected at this stage and a subset of these cells co-expressed the haemogenic endothelial markers Flk-1, VEC, CD31, CD34 and Tie2. Only a small proportion of Sox17-GFP + cells expressed Sca-1, CD41 and CD11b. Intriguingly, a subset of the Sox17-GFP population was CD45 + , suggesting that Sox17 expression marks the emerging HSCs 21 . Analyses of the yolk sac of E7.5 embryos identified a Sox17-GFP + population that co-expressed Flk-1 and CD31 ( Supplementary Fig. S2b,c) . As with the early mESC-derived population, it is unclear whether these cells represent the developing primitive erythroid lineage, the yolk sac haemogenic endothelial population recently described 22 or vascular progenitors. Analyses of E10.5 embryos by whole-mount immunostaining revealed that Sox17-GFP was present in the endothelial cells lining the arteries but not the veins ( Supplementary Fig. S2a ) as well as in all cells of the emerging haematopoietic clusters found in the dorsal aorta (Fig. 2b) Fig. 2g and Supplementary Fig. S2f ). Collectively, the findings from these in vivo studies demonstrate that expression of Sox17-GFP marks the developing haemogenic endothelium and HSCs in the AGM and that it is required for HSC development at this site.
To further investigate the role of Sox17 in the establishment of haematopoiesis, we analysed the effects of deleting its expression in vitro using a Sox17 −/− mESC line ( Supplementary Fig. S3a ). Although cell proliferation seemed to be lower in the Sox17 −/− cultures when compared with the Sox17-mC controls ( Supplementary Fig.  S3b ), Sox17
−/− Flk-1 + populations were detected at D3.25 and D5.25 (Fig. 3a) . The Sox17 −/− D3.25 Flk-1 + population exhibited normal primitive erythroid and myeloid potential, indicating that Sox17 is not required for establishment of the primitive haematopoietic program (Fig. 3b) . Analyses of the Sox17 −/− D5.25 Flk-1 + cells showed that they retained the capacity to generate adhesive populations that had haemogenic endothelial cell surface marker profiles similar to those derived from the Sox17-mC control cells (Fig. 3c, left) . Both wild-type and Sox17-null D5.25 Flk-1 + cells also gave rise to CD31 + CXCR4 − and CD31 + CXCR4 + populations thought to represent venous and arterial endothelium, respectively 23 . qRT-PCR analysis showed that the D7 Sox17 −/− cells expressed higher levels of Sox7 than the controls, suggesting that its upregulation may compensate for the loss of Sox17. Expression levels of Sox18, as well as of genes associated with arterial (EphrinB2), venous (COUP-TFII ) and haemogenic endothelial (HoxA3, Aml1c) development, and notch signalling (Notch1, Jagged1) were unaffected by the loss of Sox17 (Fig. 3d, left) .
We next sorted the D7 VEC + fraction and cultured the cells as a monolayer for 48 h to determine whether the Sox17 −/− cells could undergo the EHT. Both the Sox17
−/− and Sox17-mC control 
Sox17-mC Sox17 -/-0 0.5 Bars represent standard deviation of the mean of 3 independent experiments. D7: Sox7 * * P = 0.01. D9: Sox7 * * * P = 0.003, Sox18 * P = 0.014, EphrinB2 * * * P = 0.0004, Notch1 * * P = 0.01, Jagged1 * * * P = 0.003. (e) Haematopoietic progenitor potential of the Sox17-mCand Sox17 −/− -derived D9 aggregates. D9 cells were dissociated and plated in methylcellulose cultures, and scored for definitive erythroid (D-Ery), macrophage and monocyte (Mac), granulocyte and macrophage (GM) or granulocyte, erythrocyte, macrophage and megekaryocyte (Mixed) colonies after 8 days in culture. Bars represent standard deviation of the mean of 3 independent experiments. For mixed colonies * * * P = 0.001. (f) T-lymphoid progenitors measured on OP9-DL1 stromal cells. Bars represent standard deviation of the mean of 3 independent experiments. * * * P = 0.0001.
VEC
+ cells generated large haematopoietic CD45 + populations, demonstrating their capacity to transition to a haematopoietic fate (Fig. 3c, right) . With this transition, the size of the VEC + and CD31
+ populations in the Sox17 −/− cultures decreased markedly when compared with controls, suggesting that Sox17 is required for the maintenance of the haemogenic vasculature in vitro. qRT-PCR analyses supported this interpretation in demonstrating that expression of genes associated with endothelial development, including Sox7, Sox18, EphrinB2 and Notch1 was significantly downregulated in the Sox17 −/− population when compared with controls ( Fig. 3d, right) . No differences were detected in the expression of Runx1, HoxA3 or COUP-TFII. Colony-forming cell (CFC) assays revealed that the Sox17 −/− VEC cells were able to generate myeloid and erythroid progenitors at numbers comparable to those from the control population. In contrast, the Sox17 −/− cells generated fewer multipotential progenitors than the control cells (Fig. 3e) and showed a complete lack of T-lymphoid potential (Fig. 3f) . Collectively, these findings indicate that Sox17 is dispensable for erythroid and myeloid development from the D7 VEC + haemogenic endothelium but is required for the generation of multipotential and T-lymphoid progenitors from this population.
To gain further insight into the mechanism by which Sox17 is regulating definitive haematopoiesis we investigated the consequences of enforced expression, using a mESC line containing a doxycyclineinducible Sox17 cDNA (ref. 24) . For these studies, Sox17 was induced in the D5.25 Flk-1 + population during the 2 days of monolayer culture that promotes the expansion of haemogenic endothelium. During this culture period, untreated Flk-1 + cells gave rise to an adherent haemogenic endothelial population that initiated the EHT, as demonstrated by the emergence of round haematopoietic cells (Supplementary Fig. S4a ). In contrast, the haemogenic endothelial population generated from the doxycycline-induced Flk-1 + contained no budding haematopoietic cells. These differences were not due to an increase in cell death as total cell numbers were equal in both groups (Supplementary Fig. S4b ). The morphological changes induced by overexpression of Sox17 were mirrored by a pronounced increase in the size of the VEC + population, a significant decrease in the size of the CD45
+ VEC − population and a reduction in the frequency of myeloid and T-cell progenitors at D7 (Fig. 4a,b) . Interestingly, expression of Sox17 also led to an increase in the size of the arterial-like CD31
+ CXCR4 + population. These observations suggest that enforced expression of Sox17 results in an increase in the size of the haemogenic endothelial population and an impairment in its ability to undergo the EHT.
To determine whether the Sox17-induced haemogenic endothelial population can generate haematopoietic cells, VEC + CD45 − cells were isolated from the induced and non-induced D7 populations and cultured in the absence of doxycycline (Fig. 4a, right panel) . As expected, the non-induced VEC + cells generated a substantial VEC − CD45 + population by D9. The VEC + cells from the D7 induced monolayer also produced CD45
+ haematopoietic cells, although the size of the population was considerably smaller than that generated by the non-induced cells. The frequency of myeloid and multipotent progenitors in the non-induced and induced D9 populations was comparable, consistent with the observation that both contained CD45 + cells (Fig. 4b) . In contrast, the induced population showed a threefold higher frequency of T-lymphoid progenitors (Fig. 4c) , indicating that it exhibits enhanced definitive haematopoietic potential. Molecular analyses revealed that expression levels of EphrinB2, Notch1 and Jagged1 were significantly upregulated whereas that of COUP-TFII was reduced in the induced population at D7 of culture (Fig. 4d) . Expression of Aml1c was lower in the induced compared to noninduced population at D7. By D9, the levels had increased in both populations. Enforced expression of Sox17 had no effect on the expression of HoxA3. Collectively, these findings demonstrate that enforced expression of Sox17 leads to an increase in the size of the haemogenic endothelial population able to generate T lymphocytes and suggest that this effect may be mediated through the Notch pathway.
To investigate the role of Notch signalling in the Sox17-induced expansion of haemogenic endothelium, induced and non-induced D5 Flk-1 + cells were cultured (48 h) in the presence and absence of the pathway inhibitor γ-secretase inhibitor (γSI). The addition of γSI reduced total cell numbers as well as the size of the CD31 + CXCR4 + arterial-like endothelial population generated from both the Sox17-induced and non-induced populations ( Fig. 5a and Supplementary Fig.  S5a ). Manipulation of the Notch pathway did not, however, impact the size of the induced VEC + population. The addition of γSI did prevent the Sox17-induced changes in EphrinB2 and COUP-TFII expression (Fig. 5b) . D7 induced and non-induced VEC + CD45 − cells from γSI-treated or control cultures were next isolated, cultured as aggregates for 2 days and the resulting populations assayed for the presence of
CD45
+ cells, for Aml1c expression and for myeloid/erythroid and T-cell potential. The addition of γSI to the non-induced progenitors had no effect on the CD45 profile, the levels of Aml1c expression or the T-cell potential of the D9 population (Fig. 5c,d ). In contrast, Notch inhibition in Sox17-induced cultures markedly reduced the size of the CD45 + population, the expression levels of Aml1c and the frequency of T-cell progenitors (Fig. 5c,d and Supplementary Fig. S5b ). The addition of γSI did not, however impact the generation of myeloid and erythroid progenitors (Supplementary Fig. S5c ).
To determine whether Sox17 can directly activate Notch1, we analysed the Notch1 promoter region for motifs that can be recognized by Sox17. The JASPER database identified four Sox17-binding sites in the mouse Notch1 promoter, two (BS1 and BS2) of which are evolutionarily conserved (Fig. 5e and Supplementary Fig. S5d ) 25 . To determine whether Sox17 can activate Notch1, U2OS cells were transfected with a Sox17 expression plasmid together with a reporter construct containing a 660-base-pair (bp) region of the Notch1 promoter including the BS1 and BS2 sites upstream of luciferase. Sox17 induced luciferase activity in a dose-dependent fashion, demonstrating that Sox17 can activate the Notch1 promoter (Fig. 5f) . Mutations of the Sox-binding motif of BS1 and BS2 reduced luciferase activity, demonstrating that these sites are necessary for the Sox17-mediated activation of the Notch1 promoter.
To determine whether the loss of Sox17 also affected the levels of Notch1 expression in vivo, the AGM regions from E11. Deciphering the regulatory pathways that control the establishment of definitive haematopoiesis is essential for modelling this program in ESC differentiation cultures and ultimately to generate HSCs in vitro. Our findings have provided new insights into this process and position Sox17 as a key regulator of haemogenic endothelium. Specifically, our mESC data show that Sox17 is required for the development and/or maintenance of haemogenic endothelium able to generate T cells. Interestingly, the Sox17 −/− VEC + haemogenic endothelium did retain myeloid and erythroid potential, indicating that the specification of a subset of these progenitors is Sox17 independent. These observations suggest that Sox17 specifically regulates the subpopulation of haemogenic endothelium that gives rise to the T-lymphoid lineage, a measure of the definitive haematopoiesis, and that dependence on Sox17 distinguishes it from the haemogenic endothelium that generates myeloid and erythroid progenitors. The existence of distinct definitive progenitor populations in the mESC model is consistent with in vivo studies that showed that the formation of erythroid-myeloid progenitors and HSCs can be uncoupled on the basis of the temporal and spatial expression of CBFβ in Ly6a-expressing cells 26 . Our enforced expression studies indicate that sustained levels of Sox17 expression lead to an increase in the size of the haemogenic endothelial population able to generate T lymphocytes. A recent study using human ESCs has also provided evidence that enforced expression of Sox17 results in expansion of a population with properties of haemogenic endothelium (ref. 27 ). However, as only erythroid and myeloid potential was analysed, it is unclear whether the observed effect was on haemogenic endothelium with definitive haematopoietic potential. The demonstration that regulation of haemogenic endothelium by Sox17 may be mediated by Notch signalling is consistent with the known role of this pathway in definitive haematopoietic development 10 and positions the requirement for Notch signalling at the specification stage of haemogenic endothelium. Previous studies have identified HoxA3 as a transcriptional regulator of haemogenic endothelium and provided evidence that it functions upstream of Sox17 (ref. 9 ). The observation that HoxA3 expression was not impacted following overexpression or deletion of Sox17 in our mESC-derived populations is consistent with this interpretation.
The findings in our study support the emerging body of work demonstrating that SoxF transcription factors are regulators of different stages of embryonic haematopoiesis. At E8.0, Sox7 and Sox18 are detected in the developing paired dorsal aortae, whereas expression of Sox17 emerges in the anterior regions of the dorsal aorta at E8. 5-8.75 (refs 15,16) . Studies using mESCs have shown that Sox7 and Sox18 play a role in the regulation of primitive haematopoiesis 12, 13 . Our observation that primitive haematopoiesis was not perturbed in
Sox17
−/− cultures suggests that the function of Sox17 differs from that of Sox7 and Sox18. The differential function of these factors is supported by studies showing that the knockdown of Sox7 and Sox18 expression has no impact on the development of HSCs in zebrafish 28 suggesting that Sox17 is the sole SoxF member involved in definitive haematopoiesis.
METHODS
Methods and any associated references are available in the online version of the paper. GFP/+ and Sox17 fl/+ mice were a gift from S. Morrison (University of Texas Southwestern, USA). VEC-Cre + mice were a gift from N. Speck (University of Pennsylvania, USA). Embryos were generated through timed matings with the day of vaginal plug designated embryonic day 0.5. Pregnant dams were killed and the developmental stage of the embryos was determined by counting the number of somite pairs. Embryos with 36-40 somite pairs were used for confocal microscopy and embryos with 41-47 somite pairs were used for transplantation studies. Microscopy and imaging. Whole-mount immunohistochemistry was performed as described previously 29 . Rat anti-mouse CD31 (1:500, BD, clone MEC 13,3, cat. no. 557355) was used with goat anti-rat Alexa Flour 555 (1:1,000, Invitrogen, cat # A21434). Rabbit anti-mouse GFP (1:1,000, MBL, cat. no. 598) was used with goat anti-rabbit Alexa Flour 488 (1:1,000, Invitrogen, cat. no. A11304). Rat anti-mouse CD117 (1:250, eBioscience, clone 2B8, cat. no. 3 14-1171) was used with goat anti-rat Alexa Fluor 647 (1:1,000, Invitrogen, cat. no. A21247). Specimens were analysed with a Zeiss AxioObserver inverted microscope and images were acquired with Zeiss Zen software. mESC maintenance and differentiation. Sox17-mCherry fusion (Sox17-mC) ESCs were provided by H. Lickert, Institute of Stem Cell Research, Helmholtz Zentrum München, Germany. Sox17 −/− were provided by S. Morrison. mESC lines were maintained in serum-free/feeder-free culture conditions (SF-ES) supplemented with 2i (refs 30,31).
mESCs were differentiated in a serum-free media protocol. mESCs were trypsinized using Trypsin-LE (Invitrogen) and cultured in serum-free differentiation (SF-D) media 31 in the absence of growth factors at a concentration of 2 × 10 5 ml −1 for 48 h to form embryoid bodies. At D2, embryoid bodies were dissociated with Trypsin-LE (Invitrogen) and reaggregated at a concentration of 2 × 10 5 ml −1 in SF-D media containing recombinant human (rh) VEGF (5 ng ml −1 , R&D, cat. no. 293-VE), rhBMP4 (8 ng ml −1 , R&D cat. no. 314-BP) and ActivinA (2 ng ml −1 , R&D, cat. no. 338-AC) for 30 h. At D3+6 h, embryoid bodies were dissociated and reaggregated at a concentration of 5 × 10 5 ml −1 in 24-well ultralowattachment dishes (Corning) in SF-D containing ActA (3 ng ml −1 ) for 24 h. At D4+6 a final volume of rhVEGF (5 ng ml −1 ), rhBMP4 (10 ng ml −1 ) and the TGFβ inhibitor SB431542 (6 µM, Sigma, cat. no. S-4317) was added to the cultures. At D5+6, embryoid bodies were dissociated and the Flk-1 + cells were isolated by FACS. Haematopoietic progenitor colony assay. Cells were plated in 1% methylcellulose (wt/vol, Sigma) containing 10% (vol/vol) plasma-derived serum (PDS; Antech), 5% (vol/vol) protein-free hybridoma medium (PFHM-II; Invitrogen), transferrin (300 µg ml, Roche), glutamine (2 mM), ascorbic acid (50 µg ml −1 ), 1-thioglycerol (4.5 × 10 −4 M) and the following cytokines: KL (2% vol/vol)-conditioned medium, rmTPO (50 ng ml −1 , R&D), erythropoietin (2 U ml −1 ), rhIL11 (25 ng ml −1 , R&D, cat. no. 218-IL), IL3 (1% (vol/vol)-conditioned medium, GM-CSF (1% (vol/vol)-conditioned medium and rmIL6 (5 ng ml −1 ). Cultures were maintained at 37 • C, 5% CO 2 for 8 days. Mean and standard errors of 3 independent experiments were calculated.
OP9-DL1 co-culture assay for T-lymphoid cells. Irradiated (gamma irradiation
30 gray) OP9-DL1 cells were seeded 1 day before use on gelatin (0.1% vol/vol) 96-well tissue culture treated plates (TC, Falcon). mESC-derived progenitors were then plated as single cells in αMEM (Invitrogen) with 20% (vol/vol) FCS containing rmFlt3L (10 ng ml −1 , R&D), rmIL7 (5 ng ml −1 , R&D, cat. no. 407-ML) and 2% (vol/vol) KL-conditioned medium for the first week. Then media were changed every 5 to 7 days to αMEM containing 20% (vol/vol) FCS, rmFlt3L (10 ng ml −1 ) and rmIL7 (5 ng ml −1 ). Cultures were examined after 21 days of culture by flow cytometry. For in vitro limiting dilution analyses, the progenitor frequency was calculated using ELDA software (WEHI Bioinformatics).
Quantitative real-time PCR. Total RNA was prepared with the RNAqueousMicro Kit (Ambion) and treated with RNase-free DNase (Ambion). RNA (500 ng to 1 µg) was reverse transcribed into cDNA using random hexamers and Oligo(dT) with Superscript III Reverse Transcriptase (Invitrogen). qPCR was performed on a MasterCycler EP RealPlex (Eppendorf) using QuantiFast SYBR Green PCR Kit (Qiagen). Expression levels were normalized to the housekeeping gene β-actin (Actβ). Primer sequences are listed in Supplementary Table S1 .
Luciferase assays. Approximately 660 bp of Notch1 sequence upstream of the transcriptional start site was cloned into the pGL3-basic vector (Promega). Mutant BS1 and BS2 sites were generated by site-directed mutangenesis using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). U2OS cells (2 × 10 4 ) were plated in triplicate and transfected with 50 ng of the indicated promoter/reporter constructs, 10 ng pRL-TK, 3-30 ng pCag-Sox17 or vector control, using FuGENE 6 (Promega). After stimulation, firefly substrate activity was measured using britelite plus (PerkinElmer) and Renilla substrate activity was measured using Stop & Glo (Promega). Firefly values were normalized to Renilla and then all normalized values set relative to the pGL3 control vector. R.Clarke Supplemental Figure 1 c.
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